

Prescribing Clinical Network

| | |
|--|--|
| Policy Statement | Alimemazine tartrate (trimeprazine tartrate) for the treatment of pruritis in eczema (licensed indication) |
| Policy No: | PCN 285 - 2017 |
| Date of Issue | December - 2017 |
| Review Date: | December - 2020 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i> |
| Recommendations: <p>The PCN does not recommend Alimemazine (trimeprazine) for the treatment of pruritis in eczema</p> <p>Alimemazine (trimeprazine) will be considered BLACK, for new patients, on the traffic light system</p> <p>Patients whose treatment with Alimemazine was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant within 12 months, but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.</p> | |
| Key Considerations: <ul style="list-style-type: none"> No high level evidence available to support or refute the efficacy or safety of oral H1 antihistamines used as monotherapy for eczema. Not a cost effective use of NHS resources given the significant list price increase. Safety concerns were noted by PCN members with regards first generation H1 antihistamines. | |
| Date taken to Prescribing Clinical Network | 6 th December 2017 |
| Agreed by PCN members | 18 th December 2017 |

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG